The current study evaluated the relationship of the GPS, NLR, and BMI with treatment efficacy among patients with high PD‐L1 expression undergoing first‐line pembrolizumab monotherapy for NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.